Larimar Therapeutics (LRMR) Cash from Operations (2016 - 2020)
Historic Cash from Operations for Larimar Therapeutics (LRMR) over the last 8 years, with Q4 2020 value amounting to -$9.9 million.
- Larimar Therapeutics' Cash from Operations fell 2459.87% to -$9.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$42.2 million, marking a year-over-year decrease of 8590.69%. This contributed to the annual value of -$70.8 million for FY2024, which is 11134.33% down from last year.
- Larimar Therapeutics' Cash from Operations amounted to -$9.9 million in Q4 2020, which was down 2459.87% from -$11.2 million recorded in Q3 2020.
- Over the past 5 years, Larimar Therapeutics' Cash from Operations peaked at $3.5 million during Q2 2019, and registered a low of -$17.8 million during Q1 2016.
- Moreover, its 5-year median value for Cash from Operations was -$11.5 million (2017), whereas its average is -$10.6 million.
- Per our database at Business Quant, Larimar Therapeutics' Cash from Operations soared by 12633.71% in 2019 and then crashed by 44794.64% in 2020.
- Over the past 5 years, Larimar Therapeutics' Cash from Operations (Quarter) stood at -$8.7 million in 2016, then fell by 13.5% to -$9.8 million in 2017, then dropped by 20.31% to -$11.8 million in 2018, then surged by 33.15% to -$7.9 million in 2019, then dropped by 24.6% to -$9.9 million in 2020.
- Its Cash from Operations was -$9.9 million in Q4 2020, compared to -$11.2 million in Q3 2020 and -$12.2 million in Q2 2020.